Skip to main content
OpenTrials
Completed

NCT Number: NCT05378529

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold:

* Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD * Evaluate the distribution of Lp(a) value in participants with documented history of ASCVD by demographics and regions

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atherosclerotic Cardiovascular Disease Arterial Occlusive Diseases Arteriosclerosis Atherosclerosis Cardiovascular Diseases Vascular Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Inst. de Inv. Clinicas Bahia Blanca, Bahía Blanca, Buenos Aires, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent
  • History of ASCVD

Exclusion criteria

  • Participants known to be currently receiving investigational drug in a clinical study
  • Participants with a diagnosis of end-stage renal disease or requiring dialysis
  • Participants who have received lipoprotein apheresis to reduce Lp(a) within 3 months prior to enrollment

Treatment and study plan

Lp(a) Screening

Other

Participants will provide demographic information and have a blood draw for Lp(a) levels if they are unknown.

Primary outcomes

  1. Number of participants with elevated Lp(a) with documented history of ASCVD

    Time frame: Up to approximately 2 weeks

Secondary outcomes

  1. Lp(a) Levels

    Time frame: Up to approximately 2 weeks

    Blood sampling will be performed in cases where Lp(a) values are not available at enrollment. In cases where Lp(a) values are available, data will be collected retrospectively.

  2. Lp(a) Levels stratified by demographics and region

    Time frame: Up to approximately 2 weeks

Sponsors and collaborators

Lead sponsor

Amgen

Industry

Registry information

Official study title

A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
May 18, 2022
Registry last updated
Oct 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.